Contract Research Organizations (CROs) are witnessing a remarkable evolution in the neurology clinical trial landscape, driven by scientific innovation and increasing demand for effective treatments. The surge in trials targeting neurological disorders is not just a trend—it’s a strategic pivot driven by unmet medical needs, scientific breakthroughs, and a renewed commitment from sponsors and CROs alike.
A Market on the Rise
The global neurology clinical trials market is projected to grow from $5.84 billion in 2024 to $8.42 billion by 2030, with a compound annual growth rate (CAGR) of 6.39% per a recent Grandview Research Report. (1) This growth is fueled by the increasing prevalence of central nervous system (CNS) disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis. Notably, CNS drugs now represent 14% of the total industry pipeline, making neurology the second-largest therapeutic area in active clinical trials.
Several factors are converging to make neurology a focal point for clinical research:
CROs are playing a pivotal role in this transformation. The neurology CRO market alone is expected to reach $11.4 billion by 2032, growing at a CAGR of 6.65% according to Credence Research. (3)
Our value lies in our ability to:
Linical, a leading neuroscience CRO, exemplifies this impact. With deep therapeutic knowledge across pain, cognitive, movement, neuromuscular, and mood disorders, Linical’s global teams bring strategic insight and operational excellence to neurology and psychiatry trials. Their experience navigating complex trial designs and rare disease populations is matched by strong site relationships and alliances with key opinion leaders, imaging centers, and central labs. Linical’s adaptable project teams and proven patient recruitment strategies—across institutional settings, nursing homes, and home environments—ensure high-quality data and timely execution.
Despite the momentum, neurology trials face unique hurdles:
These challenges underscore the importance of collaboration between sponsors, CROs, investigators, and patients. We must continue to innovate in trial design, embrace patient-centric models, and advocate for regulatory flexibility.
The future of neurology trials is bright. With continued investment, strategic partnerships, and technological integration, we are entering a new era of neuroscience research—one that promises not only better treatments but also earlier diagnoses and improved quality of life for millions.
As CROs, we are not just service providers—we are strategic partners in advancing neurological care. Let’s continue to push boundaries, share insights, and work together to shape the future of clinical research.
Sources:
Author:
Alaina Dobos
Senior Clinical Trial Manager - Linical